TITLE

readers respond. Formulary and Fatigue

AUTHOR(S)
Wright, Lawrence J.
PUB. DATE
November 2010
SOURCE
PN;Nov2010, Vol. 64 Issue 11, p11
SOURCE TYPE
Trade Publication
DOC. TYPE
Letter
ABSTRACT
A letter to the editor regarding the treatment of multiple sclerosis is presented.
ACCESSION #
54408752

 

Related Articles

  • information center. Treating MS.  // PN;Oct2010, Vol. 64 Issue 10, p71 

    The article reviews the book "The Remarkable Story of Copaxone: An Approach to the Treatment of Multiple Sclerosis," by Kenneth P. Johnson.

  • Amitriptyline/methylprednisolone.  // Reactions Weekly;12/18/2010, Issue 1332, p8 

    The article describes the case of a 44-year-old man, who had secondary progressive multiple sclerosis, who experienced fatigue and dizziness while receiving steroid perfusion, referencing a study published in the November 2010 issue of the journal "Neurology."

  • diagnosis: MS. A New Era of MS Therapies?  // PN;Oct2010, Vol. 64 Issue 10, p16 

    The article focuses on the new multiple sclerosis (MS) drugs such as Gilenia from Novartis AG and Movectro from Merck Serono International SA which acquired a Russian approval. It says that Movectro has become a leading oral MS drug as compared to Gilenia, though Gilenia has been recommended by...

  • Managing multiple sclerosis. Robinson, Gina // Independent Nurse;9/6/2010, p32 

    The article reports on the management of multiple sclerosis (MS). It refers to a condition of the central nervous system (CNS) wherein the myelin sheath are damaged. Some of the symptoms are visual disturbances, continence issues and sexual dysfunction. Currently, there are no treatments for MS...

  • Evaluating the effect of HU-210 on cytokines profile and the clinical signs in the experimental model of multiple sclerosis. Aarabi, Mh; Shahaboddin, Me; Parastouci, K; Motallebi, M; Jafarnejad, A; Mirhashemi, Sm; Hamidi, Gh; Alvani, Sh // Feyz Journal of Kashan University of Medical Sciences;2013, Vol. 17 Issue 1, p1 

    Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. Recent studies have described the anti-inflammatory and immunomodulatory properties of cannabinoids. One of the synthetic components that activate cannabinoid receptors is HU-210. This study aimed to...

  • Clinical efficacy of cyclophosphamide in treatment of primary sclerosing cholangitis. CHENG Peng; YAO Jianning; WANG Chunfeng // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;dec2013, Vol. 29 Issue 12, p929 

    Objective To investigate the clinical efficacy of cyclophosphamide in the treatment of primary sclerosing cholangitis ( PSC ) . Methods Twenty - four patients with PSC who received treatment in the department of gastroenterolog in our hospital from January 2004 to December 2012 were selected as...

  • New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Nicholas, J.; Morgan-Followell, B.; Pitt, D.; Racke, M.K.; Boster, A. // Journal of Central Nervous System Disease;2012, Issue 4, p81 

    The therapeutic landscape for multiple sclerosis (MS) is rapidly changing. Currently, there are eight FDA approved disease modifying therapies for MS including: IFN-β-1a (Avonex, Rebif), IFN-β-1b (Betaseron, Extavia), glatiramer acetate (Copaxone),mitoxantrone (Novantrone), natalizumab...

  • Fatigue in multiple sclerosis: our evolving understanding of the concepts. Warner, Richard // British Journal of Neuroscience Nursing;Jun2012, Vol. 8 Issue 3, p113 

    The purpose of this paper is to explore the symptom of fatigue in multiple sclerosis (MS). Previous papers in this journal have focused on general management (Maclean, 2006), exploratory measurement techniques (Warner, 2006) and patient education programmes aimed at improving self-care ability...

  • Evaluating the effect of HU-210 on cytokines profile and the clinical signs in the experimental model of multiple sclerosis. Aarabi, Mh; Shahaboddin, Me; Parastouci, K; Motallebi, M; Jafarnejad, A; Mirhashemi, Sm; Hamidi, Gh; Alvani, Sh // Feyz Journal of Kashan University of Medical Sciences;2013, Vol. 17 Issue 1, p1 

    Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. Recent studies have described the anti-inflammatory and immunomodulatory properties of cannabinoids. One of the synthetic components that activate cannabinoid receptors is HU-210. This study aimed to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics